118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 300
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Peter S. Greenleaf M.B.A. | President, CEO & Director | 1.57M | N/D | 1970 |
Mr. Joseph M. Miller CPA | Chief Financial Officer | 883.19k | N/D | 1974 |
Mr. Matthew Maxwell Donley M.B.A. | Executive Vice President of Operations & Strategy | 901.84k | N/D | 1969 |
Mr. Stephen P. Robertson | Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer | 836.38k | N/D | 1982 |
Andrea Levin Christopher | Head of the Corporate Communications & Investor Relations | N/D | N/D | N/D |
Mr. Michael R. Martin | Chief Business Officer | 350.57k | N/D | 1972 |
Ms. Sue Evans | Senior Vice President of Global Regulatory Affairs | N/D | N/D | N/D |
Mr. Scott Habig | Chief Commercial Officer | N/D | N/D | 1960 |
Ms. DeDe Sheel | Vice President of Investor Relation | N/D | N/D | N/D |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
La calificación ISS Governance QuickScore de Aurinia Pharmaceuticals Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 5; Derechos del accionista: 2; Compensación: 10.